PIM
SAGE

Platinum Investment Management’s Sage Therapeutics SAGE Stock Holding History

Platinum Investment Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-91,933
Closed -$4.32M – 153
2023
Q2 		$4.32M Buy
91,933
+16,013
+21% +$797K 0.15% 61
2023
Q1 		$3.19M Buy
+75,920
New +$3.26M 0.11% 69

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Platinum Investment Management's SAGE Position: Q3 2023 in Review

Platinum Investment Management sold out of Sage Therapeutics (SAGE) in Q3 2023, closing a stake of 91,933 shares — an estimated $4.32M sold.

Platinum Investment Management first reported a position in SAGE in Q1 2023 and held it in 2 quarters. The position peaked at $4.32M in Q2 2023. 193 funds tracked by Wall St. Rank hold SAGE as of Q3 2023.

  • Platinum Investment Management reported no remaining Sage Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Platinum Investment Management sold 91,933 Sage Therapeutics shares in Q3 2023, an estimated $4.32M.
  • Platinum Investment Management first reported a position in Sage Therapeutics in Q1 2023 and held it in 2 quarters.
  • Platinum Investment Management's Sage Therapeutics position peaked at $4.32M in Q2 2023.
  • 193 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2023.

Based on Platinum Investment Management's 13F filing for Q3 2023, filed 3 Nov 2023.